Sensorion SA

ALSEN · PA · Healthcare / Biotechnology

8.44EUR-0.16 (-1.84%)

Price History

Full chart

Market Stats

Previous Close8.60

Open8.60

Day Range8.34 – 8.60

52-Week Range6.49 – 40.40

Volume3.74K

Market Cap68.13M

P/E (TTM)0.00

Forward P/E0.00

EPS-4.49

Dividend Yield0.00%

Beta0.41

50-Day Avg11.91

200-Day Avg16.31

About

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Frederic Chereau M.B.A.
Employees66
Headquarters375, rue du Professeur Joseph Blayac, Montpellier, France, 34080, France
Websitehttps://www.sensorion.com

Leadership

Mr. Frederic Chereau M.B.A.Chief Executive Officer · b. 1967
Ms. Laurene DanonChief Financial Officer
Mr. Bernd SchmidtChief Technical Officer
Ms. Christine Le BecHead of CMC Gene Therapy
Ms. Stephanie FilipeHead of Business Operations & Portfolio Management
Mr. Laurent DesireHead of Preclinical Development
Ms. Rachel CooperHead of Audiology

Financials

Income Statement

Currency: EUR	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	21	231.69K	356.53K	231.57K	157.51K	17.50K	1.93M	2.23M	2.46M	2.35M	4.26M	4.93M	5.70M	6.65M	0
Growth (%)	-	+1103200.00%	+53.88%	-35.05%	-31.98%	-88.89%	+10954.01%	+15.30%	+10.14%	-4.26%	+81.27%	+15.71%	+15.49%	+16.76%	-100.00%
Cost of Revenue	49.69K	627.00K	989.47K	0	3.70M	6.78M	385.36K	347.11K	303.85K	415.16K	513.51K	770.48K	955.20K	1.16M	1.36M
Gross Profit	-49.67K	231.69K	-632.93K	231.57K	-3.54M	-6.76M	1.55M	1.88M	2.15M	1.94M	3.75M	4.16M	3.79M	6.65M	-1.36M
Gross Margin	-236514.29%	100.00%	-177.52%	100.00%	-2246.43%	-38622.41%	80.08%	84.44%	87.63%	82.35%	87.96%	84.38%	66.48%	100.00%	-
Operating Expense	593.93K	1.20M	857.72K	3.10M	1.78M	2.35M	11.16M	14.19M	15.47M	13.23M	23.10M	32.27M	26.10M	35.05M	35.21M
Operating Income	-643.60K	-972.85K	-1.49M	-2.86M	-5.32M	-9.11M	-9.61M	-12.31M	-13.32M	-11.29M	-19.35M	-28.10M	-22.31M	-28.40M	-36.57M
Operating Margin	-3064766.67%	-419.89%	-418.10%	-1236.72%	-3379.05%	-52039.05%	-496.61%	-551.69%	-542.11%	-480.00%	-453.84%	-569.66%	-391.55%	-426.89%	-
EBITDA	-639.92K	-964.03K	-1.46M	-2.90M	-5.19M	-8.72M	-9.29M	-11.92M	-10.67M	-10.26M	-17.46M	-22.44M	-21.33M	-27.58M	-35.21M
EBITDA Margin	-3047219.05%	-416.08%	-410.56%	-1250.74%	-3297.78%	-49813.73%	-480.21%	-534.49%	-434.45%	-436.06%	-409.45%	-454.89%	-374.28%	-414.53%	-
Net Income	-487.16K	-987.33K	-1.65M	-3.08M	-4.27M	-7.41M	-9.69M	-12.35M	-12.10M	-8.98M	-15.14M	-23.21M	-22.06M	-25.97M	-29.43M
Net Income Margin	-2319823.81%	-426.14%	-461.88%	-1330.48%	-2711.52%	-42357.04%	-500.72%	-553.70%	-492.38%	-381.71%	-355.01%	-470.42%	-387.21%	-390.38%	-
R&D	-	711.35K	1.23M	2.27M	3.55M	5.66M	7.87M	11.91M	9.91M	7.39M	14.17M	22.27M	22.76M	25.66M	28.84M
R&D as % of Total Revenue	-	307.02%	344.25%	979.34%	2253.80%	32314.29%	406.97%	533.88%	403.35%	314.24%	332.24%	451.47%	399.37%	385.75%	-
Interest Expense	926	17.98K	163.47K	168.91K	29.40K	6.13K	232.84K	158.62K	1.34M	152.67K	188.73K	205.35K	213.70K	259.00K	262.00K
Interest Expense % of Total Revenue	4409.52%	7.76%	45.85%	72.94%	18.67%	35.00%	12.04%	7.11%	54.55%	6.49%	4.43%	4.16%	3.75%	3.89%	-

Balance Sheet

Currency: EUR	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	303.01K	378.72K	1.13M	2.19M	16.52M	11.85M	11.16M	9.47M	38.09M	67.87M	59.02M	38.93M	46.50M	89.28M	57.89M
Total Liabilities	210.51K	352.61K	2.33M	2.52M	3.70M	3.26M	3.84M	5.96M	24.88M	9.52M	15.03M	17.06M	13.23M	17.14M	13.41M
Total Equity	92.50K	26.11K	-1.20M	-323.20K	12.82M	8.59M	7.32M	3.51M	13.21M	58.35M	43.98M	21.87M	33.27M	72.14M	44.48M
Cash	129.59K	142.96K	437.49K	713.31K	13.88M	8.53M	7.59M	2.71M	25.43M	50.16M	11.97M	4.13M	36.97M	66.77M	20.67M
Total Debt	43	-	1.49M	602.45K	1.82M	975.35K	374.00K	10.87K	20.97M	3.88M	3.99M	3.76M	2.87M	2.20M	1.28M
Net Debt	-129.55K	-142.96K	1.05M	-110.86K	-12.07M	-7.55M	-7.22M	-2.70M	-4.46M	-46.28M	-7.99M	-369.80K	-34.10M	-64.57M	-19.39M

Cash Flow

Currency: EUR	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-826.03K	-1.42M	-2.30M	-5.05M	-7.19M	-7.78M	-12.25M	-14.17M	-5.31M	-10.77M	-21.41M	-21.07M	-21.33M	-27.39M
Investing Cash Flow	-7.01K	-170.00K	-666.78K	-309.74K	-491.50K	-309.41K	-272.83K	-88.25K	-164.93K	-1.07M	-1.54M	-381.06K	-11.13M	9.24M
Financing Cash Flow	846.40K	1.88M	3.25M	18.53M	2.33M	7.16M	7.64M	41.97M	37.23M	-715.07K	-820.68K	32.20M	62.26M	-1.16M
Capital Expenditure	7.01K	158.98K	666.95K	158.74K	533.14K	165.90K	14.59K	74.50K	164.93K	1.04M	1.51M	868.73K	1.12M	253.00K
Free Cash Flow	-833.04K	-1.57M	-2.97M	-5.21M	-7.73M	-7.95M	-12.26M	-14.24M	-5.48M	-11.81M	-22.92M	-21.94M	-22.45M	-27.64M
Dividends Paid	-	-	-	17.27M	378.60K	6.70M	8.01M	-	97.58K	123.96K	-	-	-	-
FCF to OCF	100.85%	111.23%	128.94%	103.14%	107.41%	102.13%	100.12%	100.53%	103.10%	109.67%	107.07%	104.12%	105.26%	100.92%
Dividend Paid to FCF	-	-	-	-331.37%	-4.90%	-84.38%	-65.35%	-	-1.78%	-1.05%	-	-	-	-

Earnings

Report Date	Jul 28, 2016	Oct 15, 2016	Sep 7, 2017	Oct 18, 2017	Apr 12, 2018	Oct 18, 2018	May 13, 2019	Oct 31, 2019	Apr 2, 2020	Oct 21, 2020	Mar 18, 2021	Jun 2, 2021	Sep 27, 2021	Dec 1, 2021	Mar 31, 2022	Apr 28, 2022	Aug 14, 2022	Nov 30, 2022	Jan 3, 2023	Jun 7, 2023	Sep 20, 2023	Nov 29, 2023	Mar 14, 2024	May 29, 2024	Sep 18, 2024	Nov 27, 2024	Mar 14, 2025	May 28, 2025	Sep 17, 2025	Dec 3, 2025	Mar 12, 2026	Mar 31, 2026	Jun 30, 2026
EPS Estimate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.06	0.00	-0.13	0.00	-0.12	-0.12	-	0.00	-0.11	0.00	-144.00	-0.18	-0.06	0.00	-0.07	0.00	-0.05	0.00	0.00	0.00	-0.05	-0.02	-0.01
EPS Actual	-0.57	-0.68	-0.70	-0.66	-1.37	-0.62	-0.48	-0.40	-0.28	-0.09	-0.06	0.00	-0.08	0.00	-0.12	-0.12	-0.15	0.00	-0.14	0.00	-0.15	0.00	-0.06	0.00	-0.07	0.00	-0.04	0.00	-0.05	0.00	0.00	-	-
Surprise	-	-	-	-	-	-	-	-	-	-	0.00%	-	38.46%	-	0.00%	0.00%	-	-	-27.27%	-	99.90%	100.00%	0.00%	-	0.00%	-	20.00%	-	-	-	100.00%	-	-
Timing	-	Pre-market	-	After-hours	Pre-market	After-hours	-	After-hours	Pre-market	Pre-market	Pre-market	-	Pre-market	-	-	Pre-market	Pre-market	-	Pre-market	Pre-market	Pre-market	-	-	-	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap68.13M

Enterprise Value34.78M

Trailing P/E0.00

Forward P/E0.00

Price / Sales11.07

Price / Book1.82

EPS-4.49

Book Value7.92

Revenue (TTM)6.16M

Gross Profit (TTM)6.16M

EBITDA-34.40M

Profit Margin0.00%

Operating Margin-802.92%

Return on Equity-49.26%

Return on Assets-25.39%

Shares Outstanding10.31M

Shares Float6.02M

Beta0.41

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Sep 15, 20261:50